特发性膜性肾病不同病理分期患者抑郁、焦虑状态研究

Study on depression and anxiety status in patients with idiopathic membranous nephropathy

关键词:  抑郁  焦虑  特发性膜性肾病

Key words:  depression  anxiety  idiopathic membranous nephropathy

摘要:

[目的] 研究特发性膜性肾病（IMN）不同病理分期患者的焦虑状态、抑郁状态发生情况。[方法] 随机选择上海中医药大学附属龙华医院2018年1月—2018年11月住院及门诊诊治的IMN病患100例，结合患者的病理诊断结果，参照Ehrenreich-Churg的分期标准，将其分为Ⅰ-Ⅱ期组、Ⅲ-Ⅳ期组。应用抑郁自评量表（SDS）、焦虑自评量表（SAS）对其进行抑郁及焦虑状态评估。[结果] IMNⅠ-Ⅱ期组患者SAS评分为（47.92±8.01）分，IMN Ⅲ-Ⅳ期组患者评分为（48.84±2.41）分，两组差异具有统计学意义（P<0.05）；IMNⅠ-Ⅱ期组患者SDS评分为（41.32±5.28）分，IMN Ⅲ-Ⅳ期组患者评分为（55.84±8.37）分，两组差异有统计学意义（P<0.05）。IMN患者的SDS、SAS总体评分高于国内正常人群评分，差异有统计学意义（P<0.05）。[结论] IMN患者存在不同程度的焦虑、抑郁状态，利用有效的护理、心理治疗等措施对IMN各期患者心理状况进行干预，可缓解其焦虑及抑郁程度，并有效提高生活状态，改善疾病预后。

Abstract:

[Objective] To study the incidence of anxiety and depression in patients with different pathological stages of Idiopathic membranous nephropathy (IMN).[Methods] One hundred cases of IMN patients hospitalized and outpatients from January 2018 to November 2018 in Longhua hospital affiliated to Shanghai university of traditional Chinese medicine were randomly selected. Combined with the pathological diagnosis results of patients, the Ehrenreich-Churg staging criteria were divided into group I-II and group III~IV. Depression and anxiety status were assessed using the self-rating depression scale (SDS) and the self-rating anxiety scale (SAS).[Results] The SAS score of the IMN I~II group was 47.92±8.01, and the score of the IMN III~IV group was 48.84±2.41. The difference between the two groups was statistically significant (P<0.05). The SDS score was 41.32±5.28 in the IMN I-II group and 55.84±8.37 in the IMN III~IV group. The difference between the two groups was statistically significant (P<0.05). The overall scores of SDS and SAS in IMN patients were higher than those in normal population in China, and the difference was statistically significant (P<0.05).[Conclusion] Patients with IMN have different degrees of anxiety and depression. Interventions such as effective nursing and psychotherapy can improve the anxiety and depression of patients with IMN, and effectively improve their living conditions and improve the prognosis of the disease.